<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869645</url>
  </required_header>
  <id_info>
    <org_study_id>TP18-0009</org_study_id>
    <nct_id>NCT03869645</nct_id>
  </id_info>
  <brief_title>CAPERE Thrombectomy System Post-Market Clinical Follow Up Study</brief_title>
  <official_title>CAPERE Thrombectomy System Post-Market Clinical Follow Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Medcure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Medcure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, non-blinded study, intending to collect and evaluate data in up to&#xD;
      forty (40) human subjects with acute thrombosis, treated with the CAPERE™ Thrombectomy&#xD;
      System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, non-blinded study, intending to collect and evaluate data in up to&#xD;
      forty (40) human subjects with acute thrombosis, treated with the CAPERE™ Thrombectomy&#xD;
      System.&#xD;
&#xD;
      Subjects will be evaluated based on VEINES QoL survey pre- and post-treatment (30-days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of blood flow</measure>
    <time_frame>Day 0 - Intervention</time_frame>
    <description>Clearance of clot and restoration of venous flow of the affected vessel as confirmed using venogram immediately post-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VEINES Survey</measure>
    <time_frame>&lt;/= Day 0 and Day 30</time_frame>
    <description>Evaluation of quality of life (QoL) before and after treatment based on VEINES survey responses. Eight (8) QoL questions related to the patient's leg problems are evaluated and their scores aggregated into a single QoL score. The resultant aggregated QoL range is from 26 - 108 where the higher the number the higher the quality of life.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Observational Study</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CAPERE Thrombectomy System</intervention_name>
    <description>Mechanical thrombectomy of acute thrombus in peripheral vasculature with the CAPERE Thrombectomy System</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with clinical symptoms of extremity swelling with ultrasound evidence of&#xD;
        acute thrombosis in the peripheral vasculature.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are &gt; 18 years of age&#xD;
&#xD;
          -  Patients with clinical signs, symptoms and presentation consistent with acute&#xD;
             thrombosis; onset of symptoms &lt; 14 days&#xD;
&#xD;
          -  Patients cleared medically for invasive endovenous procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with IVC filter in area to be treated&#xD;
&#xD;
          -  Patients who are &lt; 18 years of age.&#xD;
&#xD;
          -  Known anaphylactic reaction of radiographic contrast agents that cannot be pre-&#xD;
             treated&#xD;
&#xD;
          -  Imaging evidence or other evidence that suggests the participant is not appropriate&#xD;
             for mechanical thrombectomy intervention&#xD;
&#xD;
          -  Female who is pregnant or nursing&#xD;
&#xD;
          -  Concurrent participation in another investigational drug or device treatment study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiffany Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey P DuMontelle</last_name>
    <phone>7149150886</phone>
    <email>jeff@vascularmedcure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Chung, BSN RN CCRC</last_name>
      <phone>714-744-8795</phone>
      <email>Sandy.Chung@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Tiffany Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

